Cost-effectiveness analysis of magnetic resonance-guided focused ultrasound ablation for palliation of refractory painful bone metastases. (3rd December 2020)

• Record Type: Journal Article
• Authors: Bucknor, Matthew D.; Chan, Frandics P.; Matuoka, Jessica Y.; Curl, Patti K.; Kahn, James G.
• Is Part Of: International journal of technology assessment in health care. Volume 37:Number 1(2021)
• Publication Date: 2020-12-03
• Subjects: Magnetic resonance-guided focused ultrasound (MRgFUS), -- High-intensity focused ultrasound, -- Thermal ablation, -- Bone metastases; Medical technology -- Periodicals; Technology assessment -- Periodicals; 610.28
• DOI: 10.1017/S0266462320001907
• Languages: English
• ISSNs: 0266-4623

Abstract

Abstract: Objective: The aim of this study was to determine if magnetic resonance-guided focused ultrasound (MRgFUS) is cost-effective compared with medication, for refractory pain from bone metastases in the United States. Methods: We constructed a Markov state transition model using TreeAge Pro software (TreeAge Software, Inc., Williamstown, MA, USA) to model costs, outcomes, and the cost-effectiveness of a treatment strategy using MRgFUS for palliative treatment of painful bone metastases compared with a Medication Only strategy (Figure 1). Model transition state probabilities, costs (in 2018 US$), and effectiveness data (quality-adjusted life-years [QALYs]) were derived from available literature, local expert opinion, and reimbursement patterns at two U.S. tertiary academic medical centers actively performing MRgFUS. Costs and QALYs, discounted at three percent per year, were accumulated each month over a 24-month time horizon. One-way and probabilistic sensitivity analyses were performed. Results: In the base-case analysis, the MRgFUS treatment strategy costs an additional $11, 863 over the 2-year time horizon to accumulate additional 0.22 QALYs, equal to a $54, 160/QALY ICER, thus making MRgFUS the preferred strategy. One-way sensitivity analyses demonstrate that for the base-case analysis, the crossover point at which Medication Only would instead become the preferred strategy is $23, 341 per treatment. Probabilistic sensitivity analyses demonstrate that 67 percent of model iterations supported the conclusion of the base case. Conclusions: Our model demonstrates that MRgFUS is cost-effective compared with Medication Only for palliation of painful bone metastases for patients with medically refractory metastatic bone pain across a range of sensitivity analyses.